A novel pH sensitive theranostic PLGA nanoparticle for boron neutron capture therapy in mesothelioma treatment.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
12 01 2023
12 01 2023
Historique:
received:
13
11
2022
accepted:
04
01
2023
entrez:
12
1
2023
pubmed:
13
1
2023
medline:
17
1
2023
Statut:
epublish
Résumé
This study aims to develop poly lactic-co-glycolic acid (PLGA) nanoparticles with an innovative imaging-guided approach based on Boron Neutron Capture Therapy for the treatment of mesothelioma. The herein-reported results demonstrate that PLGA nanoparticles incorporating oligo-histidine chains and the dual Gd/B theranostic agent AT101 can successfully be exploited to deliver a therapeutic dose of boron to mesothelioma cells, significantly higher than in healthy mesothelial cells as assessed by ICP-MS and MRI. The selective release is pH responsive taking advantage of the slightly acidic pH of the tumour extracellular environment and triggered by the protonation of imidazole groups of histidine. After irradiation with thermal neutrons, tumoral and healthy cells survival and clonogenic ability were evaluated. Obtained results appear very promising, providing patients affected by this rare disease with an improved therapeutic option, exploiting PLGA nanoparticles.
Identifiants
pubmed: 36635364
doi: 10.1038/s41598-023-27625-0
pii: 10.1038/s41598-023-27625-0
pmc: PMC9837127
doi:
Substances chimiques
Glycols
0
Histidine
4QD397987E
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
620Informations de copyright
© 2023. The Author(s).
Références
J Am Chem Soc. 2020 May 20;142(20):9396-9407
pubmed: 32323984
J Control Release. 2014 Jul 10;185:71-87
pubmed: 24768790
Future Med Chem. 2016 May;8(8):899-917
pubmed: 27195428
Langmuir. 2018 Nov 20;34(46):13935-13945
pubmed: 30351968
Anticancer Res. 2016 Mar;36(3):907-11
pubmed: 26976977
Target Oncol. 2022 Jul;17(4):407-431
pubmed: 35906513
Biomacromolecules. 2013 May 13;14(5):1434-43
pubmed: 23627834
Radiat Oncol. 2012 Aug 29;7:146
pubmed: 22929110
Front Oncol. 2022 Mar 31;12:788770
pubmed: 35433432
Sci Rep. 2017 Mar 31;7:45768
pubmed: 28361969
Crit Rev Oncol Hematol. 2011 May;78(2):92-111
pubmed: 20466560
Bioorg Med Chem. 2005 Feb 1;13(3):735-43
pubmed: 15653341
Eur Respir Rev. 2015 Mar;24(135):115-31
pubmed: 25726562
Pharm Res. 2015 Feb;32(2):362-74
pubmed: 25092068
Life (Basel). 2021 Apr 10;11(4):
pubmed: 33920126
ACS Omega. 2022 Jan 12;7(3):2533-2553
pubmed: 35097254
Chem Rev. 2019 Jan 23;119(2):957-1057
pubmed: 30350585
ChemMedChem. 2017 Apr 6;12(7):502-509
pubmed: 28217982
Oncotarget. 2017 May 17;8(32):53751-53762
pubmed: 28881848
Int J Part Ther. 2022 Jun 9;9(1):71-82
pubmed: 35774489
Nanomedicine. 2015 Apr;11(3):741-50
pubmed: 25596074
J Mater Chem B. 2019 Jan 7;7(1):30-42
pubmed: 32254948
Chemistry. 2011 Jul 18;17(30):8479-86
pubmed: 21671294
Front Pharmacol. 2018 Nov 02;9:1260
pubmed: 30450050
Br J Radiol. 2015 Oct;88(1054):20150207
pubmed: 25969868
J Mater Chem B. 2021 Jun 23;9(24):4863-4872
pubmed: 34095943
Mol Pharm. 2014 Nov 3;11(11):4100-6
pubmed: 25225751
Chem Soc Rev. 2019 Jul 1;48(13):3497-3512
pubmed: 31214680
Int J Radiat Oncol Biol Phys. 2006 Dec 1;66(5):1584-9
pubmed: 17056195
J Control Release. 2018 Jun 28;280:31-38
pubmed: 29730155
Org Biomol Chem. 2008 Dec 7;6(23):4460-6
pubmed: 19005608
Cell Cycle. 2009 Feb 1;8(3):505-6
pubmed: 19176997
Eur J Pharm Biopharm. 2015 Jun;93:37-45
pubmed: 25794477
CA Cancer J Clin. 2019 Sep;69(5):402-429
pubmed: 31283845
Curr Med Chem. 2019 Jun 03;:
pubmed: 31161983
Angew Chem Int Ed Engl. 2021 Feb 19;60(8):4208-4214
pubmed: 33186484
Chemistry. 2018 Mar 2;24(13):3122-3126
pubmed: 29194843
Int J Hyperthermia. 1995 Mar-Apr;11(2):211-6
pubmed: 7790735
Appl Radiat Isot. 2009 Jul;67(7-8 Suppl):S3-6
pubmed: 19467879